Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025)
Editas Medicine's (EDIT) quarterly Income from Continuing Operations came in at 30270000.0 in Q3 2025, up 51.28% year-on-year from 20008688.33 in Q3 2024, and up 41.75% on a QoQ basis from 51962000.0 in Q2 2025.
Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Income from Continuing Operations data on file, last reported at 30270000.0 in Q3 2025.
- On a quarterly basis, Income from Continuing Operations rose 51.28% year-over-year to 30270000.0 in Q3 2025; TTM through Sep 2025 was 219245000.0, a 1.52% decrease from a year earlier, with the FY2024 full-year figure at 255537000.0, up 46.79% from the prior year.
- Income from Continuing Operations for Q3 2025 stood at 30270000.0, up from 51962000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for EDIT reached as high as 20424000.0 in Q4 2023 and fell as low as 4005050000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 444906157.89 across 5 years, with a median of 67606000.0 in 2024.
- Across the five-year window, Income from Continuing Operations tumbled 3901.13% in 2022 and jumped 92.91% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 33717000.0 in 2021, then sank by 71.62% to 57865000.0 in 2022, then soared by 64.7% to 20424000.0 in 2023, then plunged by 184.76% to 58160000.0 in 2024, then soared by 47.95% to 30270000.0 in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 30270000.0 in Q3 2025, 51962000.0 in Q2 2025, and 78853000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Editas Medicine | 235.14 Mn | 88.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.27 Mn |
| Jun 30, 2025 | -51.96 Mn |
| Mar 31, 2025 | -78.85 Mn |
| Dec 31, 2024 | -58.16 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -65.80 Mn |
| Dec 31, 2023 | -20.42 Mn |
| Sep 30, 2023 | -132.82 Mn |
| Jun 30, 2023 | -506.50 Mn |
| Mar 31, 2023 | -283.96 Mn |
| Dec 31, 2022 | -57.87 Mn |
| Sep 30, 2022 | -1.59 Bn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -4.01 Bn |
| Dec 31, 2021 | -33.72 Mn |
| Sep 30, 2021 | -67.50 Mn |
| Jun 30, 2021 | -130.67 Mn |
| Mar 31, 2021 | -100.10 Mn |
| Dec 31, 2020 | -67.65 Mn |